公开(公告)号：US20120045517A1

公开(公告)日：2012-02-23

申请号：US13285439

申请日：2011-10-31

申请人： Michael Richard Simon ,  Mark Andrew Kroenke

发明人： Michael Richard Simon ,  Mark Andrew Kroenke

IPC分类号： A61K39/395 ,  A61P3/00 ,  A61K9/50

CPC分类号： C07K16/065 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/52

摘要： A process for inhibiting symptoms of a subject with celiac disease is provided that includes administration of monoclonal-, or polyclonal-, monomeric, dimeric, or polymeric IgA. Joining secretory component to the IgA limits oral administration degradation. Formulating agents are mixed with the monomeric, dimeric, or polymeric IgA to yield a dosing form of a capsule, tablet, and a suppository. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating.

摘要翻译： 提供了一种用于抑制患有乳糜泻症的受试者症状的方法，其包括施用单克隆抗体或多克隆单体二聚体或聚合物IgA。 将分泌组分连接至IgA限制口服给药降解。 将制剂与单体，二聚体或聚合物IgA混合以产生胶囊，片剂和栓剂的给药形式。 该治疗剂适于直接通过微胶囊包被或剂量形式用肠溶衣包被。

公开(公告)号：US08119104B2

公开(公告)日：2012-02-21

申请号：US13013648

申请日：2011-01-25

申请人： Michael Richard Simon ,  Mark Andrew Kroenke

发明人： Michael Richard Simon ,  Mark Andrew Kroenke

IPC分类号： A61K49/00 ,  A61K39/395 ,  A61K39/40

CPC分类号： C07K16/065 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/52

摘要： A process for inhibiting symptoms of a subject with celiac disease is provided that includes administration of monoclonal-, or polyclonal-, monomeric, dimeric, or polymeric IgA. Joining secretory component to the IgA limits oral administration degradation. Formulating agents are mixed with the monomeric, dimeric, or polymeric IgA to yield a dosing form of a capsule, tablet, and a suppository. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating.

摘要翻译： 提供了一种用于抑制患有乳糜泻症的受试者症状的方法，其包括施用单克隆抗体或多克隆单体二聚体或聚合物IgA。 将分泌组分连接至IgA限制口服给药降解。 将制剂与单体，二聚体或聚合物IgA混合以产生胶囊，片剂和栓剂的给药形式。 该治疗剂适于直接通过微胶囊包被或剂量形式用肠溶衣包被。

公开(公告)号：US08313730B2

公开(公告)日：2012-11-20

申请号：US13285439

申请日：2011-10-31

申请人： Michael R. Simon ,  Mark Andrew Kroenke

发明人： Michael R. Simon ,  Mark Andrew Kroenke

IPC分类号： A61K49/00 ,  A61K39/395 ,  A61K39/40

CPC分类号： C07K16/065 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/52

摘要： A process for inhibiting symptoms of a subject with celiac disease is provided that includes administration of monoclonal-, or polyclonal-, monomeric, dimeric, or polymeric IgA. Joining secretory component to the IgA limits oral administration degradation. Formulating agents are mixed with the monomeric, dimeric, or polymeric IgA to yield a dosing form of a capsule, tablet, and a suppository. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating.

公开(公告)号：US20110117143A1

公开(公告)日：2011-05-19

申请号：US13013648

申请日：2011-01-25

申请人： Michael Simon ,  Mark Andrew Kroenke

发明人： Michael Simon ,  Mark Andrew Kroenke

IPC分类号： A61K39/395 ,  A61K9/00 ,  A61P3/00

CPC分类号： C07K16/065 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/52

摘要： A process for inhibiting symptoms of a subject with celiac disease is provided that includes administration of monoclonal-, or polyclonal-, monomeric, dimeric, or polymeric IgA. Joining secretory component to the IgA limits oral administration degradation. Formulating agents are mixed with the monomeric, dimeric, or polymeric IgA to yield a dosing form of a capsule, tablet, and a suppository. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating.

摘要翻译： 提供了一种用于抑制患有乳糜泻症的受试者症状的方法，其包括施用单克隆抗体或多克隆单体二聚体或聚合物IgA。 将分泌组分连接至IgA限制口服给药降解。 将制剂与单体，二聚体或聚合物IgA混合以产生胶囊，片剂和栓剂的给药形式。 该治疗剂适于直接通过微胶囊包被或剂量形式用肠溶衣包被。